undamentalytics Newsletter
Sign in

Core Laboratories Inc. (CLB) stock

Add to watchlist

Add holding +

NYSE: CLB NYSE Oil & Gas Equipment & Services Next results ~February 3, 2027

C Fundamentals grade

Core Laboratories Inc. is a US-listed company in the oil & gas equipment & services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$9.6

Cash-flow model

Base case. Range ~$6.6–$13 across our lower- and higher-growth cases (-3%–7% a year).

Price vs value

Modestly overvalued

The price is inside our value range, 6% above our base value.

Price used: $10.19, November 2, 2026

Core Laboratories Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 0 selling1 purchase and 0 sales by directors and officers, last 12 monthsInsider trades
  • Funds84 adding, 100 cuttingOf 27 active managers that changed their stake, 10 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Core Laboratories files

10-Q filed October 30: Core Laboratories

Model value +3.4%

Revenue for the twelve months to September 2026 was $517m, down 0.1% on a year earlier, about the same pace as a quarter earlier. Free-cash-flow margin fell to 2.0% from 7.4% a year earlier. Operating margin narrowed to 7.5% from 10.6%. Our model value rises from $9.08 to $9.39 a share, against a share price of $10.64. The rating stays Hold. At that price, our model says the market is pricing in about 3.3% a year of cash-flow growth for five years, close to the 1.9% a year revenue growth it has delivered.

Source: 10-Q filed October 30, 2026 on SEC EDGAR · Financials · Valuation

Earlier notes (2)

10-Q filed July 30: Core Laboratories

Core Laboratories reported revenue of $517m for the twelve months to June 2026, down 0.1% on a year earlier and little changed from the pace seen a quarter earlier. Profitability has weakened more noticeably: free-cash-flow margin dropped to 2.0% from 7.4%, while operating margin narrowed to 7.5% from 10.6%. Little has moved in our valuation, with the model value sitting at $9.08 a share against a current price of $10.37. We retain our Hold rating. At today's price, the market appears to be pricing in cash-flow growth of around 3.9% a year over five years, not far off the 1.9% a year revenue growth the company has actually delivered.

10-Q on SEC EDGAR

Where Core Laboratories stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $519m, up 0.3% on a year earlier, slower than the 1.3% growth a quarter earlier. Free-cash-flow margin fell to 2.9% from 8.1% a year earlier. Against its peers on growth, profitability, cash generation and balance sheet, it grades C. It passes 2 of our 5 financial-health checks. Our cash-flow model value is $9.08 a share, against a share price of $10.16. At that price, our model says the market is pricing in about 3.6% a year of cash-flow growth for five years, close to the 2.0% a year revenue growth it has delivered.

10-Q on SEC EDGAR

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~February 3, 2027 (estimated)

Core Laboratories Inc.'s trailing-twelve-month revenue fell 0.1% year on year, with a free-cash-flow margin of 2.0%.

Our discounted-cash-flow model values the business at ~$9.6 per share in the base case (~$6.6–$13 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 72.9% while net income fell 51.6%: a 21pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Shrinking share count. Diluted shares fell 1.1% in a year, so each share owns more of the business.

Things to watch

  • Revenue shrinking. Revenue fell 0.1% over the last 12 months.
  • Margins narrowing. Operating margin is down 3.1 points on a year ago.
  • Volatile shares. Over the past year the shares showed annualised volatility of 46% and a beta of 0.8 against the S&P 500.
  • Weak cash conversion. Free cash flow was 67% of net income over the last 12 months.
  • Below peers: gross margin. Gross margin of 19.1% ranks 16 of 21 oil & gas equipment & services companies we cover (median 21.5%).
  • Heavily shorted. 25.7% of the shares available to trade are sold short (7.2 days of average volume to cover).

Latest results: FY2026 Q3

Filed October 30, 2026
Earnings per share
$0.16 against an average estimate of $0.16: beat by 0.0%
Revenue
$132m, down 1.8% on a year earlier
Share reaction
+0.7% in the first session after the results on October 28, 2026, against 0.0% for the S&P 500
Guidance given
revenue $81,000,000 to $85,000,000 (fourth quarter 2026); operating income $5,100,000 to $8,300,000 (fourth quarter 2026)
Next report
October 28, 2026; average EPS estimate $0.17

Core Laboratories' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-4.2%
  • 1 week-0.3%
  • 1 month+2.7%
  • This year-36.3%
  • 1 year-35.9%
  • 5 years-61.7%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$517M
Operating margin
7.5%
Net margin
3.0%
EPS (TTM, diluted)
$0.33

Growth

Revenue growth
−0.1%
Change in growth rate
−0.5 pts
Share count change
−1.1%

Cash

Free cash flow (TTM)
$10.4M
FCF margin
2.0%
Stock pay % of revenue
1.6%

Earnings

Last results
October 28, 2026
Next results (est.)
February 3, 2027

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Guidance
  3. Leadership
  4. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Core Laboratories Inc. valuation models and calculator

What the price is pricing in

The share price implies about 2.1% a year of cash-flow growth for five years.That is close to the 1.9% a year revenue growth Core Laboratories has delivered.

  • Priced in2.1%
  • Last 12 months-0.1%
  • 3 years a year0.5%
  • 5 years a year1.9%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($9.96, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Hold12-month view
12-month price target
~$9.6
Price used
$9.96close November 3, 2026
Implied change
▼ 4%
Uncertainty
Medium

How we got here: a discounted-cash-flow model of Core Laboratories Inc.'s free cash flow after stock-based pay with after-tax interest added back ($33.3M, FY2026 Q3 TTM), growing -1% and 2.1% in the next two years (forecasts, guidance and its record), then back to 2% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$6.6–~$13 ; that spread sets a 25% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Core Laboratories Inc.'s free cash flow after stock-based pay ( $33.3M, FY2026 Q3 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Core Laboratories Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.4%: the 10-year Treasury yield (4.9%) plus a beta of 0.98 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$9.6 ~$6.6–$13 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$9.6 ~$8.7–$12 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. ~$8.8 ~$6.0–$13 Included
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$8.9 ~$7.7–$11 Included
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$9.3 ~$8.8–$9.6 4 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Core Laboratories Inc. with Oil & Gas Equipment & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −37%
  • Revenue growth 5 points higher ▲ +48%
  • Free-cash-flow margin 1 point lower ▼ −39%
  • Last year's free-cash-flow margin change, if it persists ▼ −68%
  • Discount rate 1 point higher ▼ −21%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $8$12$17$24$32$43
8.5% $6$9$12$17$23$31
10% $4$6$9$13$17$23

Valuation multiples over time Market data may be delayed

At fiscal year end 20212022202320242025Now
Share price$22.06$20.08$17.53$17.22$15.99$10.19
Market value$1.0bn$940m$833m$821m$752m$475m
+ Net debt (− = net cash)−$18m$160m$151m$109m$90m$93m
Enterprise value$1.0bn$1.1bn$984m$930m$843m$569m
Multiples
Price / sales 2.2x1.9x1.6x1.6x1.4x0.9x
Price / earnings 52.2x48.3x22.7x26.2x25.4x30.5x
Price / free cash flow 44.7x63.8x58.6x18.5x29.1x45.9x
EV / EBITDA 15.9x18.7x14.0x12.7x11.8x10.5x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $0.51 −32% $512m −3%
Next $0.69 +36% $525m +3%

Next year's EPS estimate has moved −19.3% in 90 days, across 3 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −6.2% on 90 days ago. In the last 30 days, 1 analyst raised Core Laboratories Inc.'s forecast and 0 cut it.

Consensus EPS forecast Core Laboratories Inc., last 90 days
$0.40 $0.60 $0.80 $1.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $0.54 Current fiscal year, 60 days ago: $0.43 Current fiscal year, 30 days ago: $0.46 Current fiscal year, 7 days ago: $0.46 Current fiscal year, Now: $0.51 $0.51 Next fiscal year, 90 days ago: $0.85 Next fiscal year, 60 days ago: $0.68 Next fiscal year, 30 days ago: $0.70 Next fiscal year, 7 days ago: $0.70 Next fiscal year, Now: $0.69 $0.69

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $0.54$0.85
60 days ago $0.43$0.68
30 days ago $0.46$0.70
7 days ago $0.46$0.70
Now $0.51$0.69

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 $0.16 $0.16 0.0%
Jun 2026 $0.09 $0.11 +26.9%
Mar 2026 $0.11 $0.06 −45.5%
Dec 2025 $0.19 $0.21 +10.5%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, October 28, 2026
  • revenue fourth quarter 2026 $128,500,000 to $134,500,000
    “Core's fourth quarter 2026 revenue is projected to range from $128,500,000 to $134,500,000, with operating income of $10,700,000 to $15,100,000, yielding operating margins of approximately 10%.” source
  • EPS fourth quarter of 2026 $0.12 to $0.20
    “EPS for the fourth quarter of 2026 is expected to be $0.12 to $0.20.” source
  • operating margins fourth quarter 2026 about 10%
    “Core's fourth quarter 2026 revenue is projected to range from $128,500,000 to $134,500,000, with operating income of $10,700,000 to $15,100,000, yielding operating margins of approximately 10%.” source
  • revenue · Reservoir Description fourth quarter 2026 $81,000,000 to $85,000,000
    “Reservoir Description's fourth quarter 2026 revenue is projected to range from $81,000,000 to $85,000,000, with operating income of $5,100,000 to $8,300,000.” source
  • operating income · Reservoir Description fourth quarter 2026 $5,100,000 to $8,300,000
    “Reservoir Description's fourth quarter 2026 revenue is projected to range from $81,000,000 to $85,000,000, with operating income of $5,100,000 to $8,300,000.” source
  • revenue · Production Enhancement fourth quarter $47,500,000 to $49,500,000
    “Production Enhancement's fourth quarter revenue is estimated to range from $47,500,000 to $49,500,000, with operating income of $5,500,000 to $6,700,000.” source
Show 3 more items
  • operating income · Production Enhancement fourth quarter $5,500,000 to $6,700,000
    “Production Enhancement's fourth quarter revenue is estimated to range from $47,500,000 to $49,500,000, with operating income of $5,500,000 to $6,700,000.” source
  • operating income fourth quarter 2026 $10,700,000 to $15,100,000
    “Core's fourth quarter 2026 revenue is projected to range from $128,500,000 to $134,500,000, with operating income of $10,700,000 to $15,100,000, yielding operating margins of approximately 10%.” source
  • effective tax rate fourth quarter of 2026 about 25%
    “The Company's guidance is based on projections for underlying operations and excludes gains and losses in foreign exchange, and assumes an effective tax rate of 25%.” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

How our valuation uses these forecasts

Our cash-flow model grows Core Laboratories Inc.'s revenue by -1.0% next year and +2.1% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+0.9%, weight 37%) , management guidance (-4.9%, weight 37%) and the company's own record (+2.0%, weight 25%) . How the weights are set.

Analyst recommendations

3 analysts, Oct 2026
Buy267%
Hold00%
Sell133%

Monthly trend

  1. Oct 20261113
  2. Sep 20261113
  3. Aug 20261113
  4. Jul 20261113

Counts of recommendations published by analysts covering Core Laboratories Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
25.7%
of tradable shares
Days to cover
7.16
at average volume
Short interest, 1 month
+12%
to October 15, 2026
Held by institutions
—
of shares
Held by insiders
1.4%
of shares
Employees
3,300
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months −35.9%

$15.90 on October 31, 2025 to $10.19

ThenNowEffect
Revenue (last 12 months) $517m $519m +0.3%
Net margin 5.7% 4.7% −18.1%
P/E multiple 25.4x 19.6x −23.0%
Share count 47m 47m +1.3%

Biggest factor: p/e multiple.

Last 3 years −51.4%

$20.95 on November 3, 2023 to $10.19

ThenNowEffect
Revenue (last 12 months) $510m $519m +1.8%
Net margin 7.7% 4.7% −39.5%
P/E multiple 25.1x 19.6x −22.0%
Share count 47m 47m +1.2%

Biggest factor: net margin.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
CLB−16%−9%−13%−2%−7%−36%
Industry peers (median)+9%+49%−6%−9%+3%+19%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
CLB33%50%33%50%50%27%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
CLB−54%−62%−39%−33%−52%−52%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 94% from May 21, 2018 to March 17, 2020. Getting back needed a 1445% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$9.40 – $19.63
From 52-week high
−48.1%
vs 50-day average
−6.9%
vs 200-day average
−26.2%
Volatility (1 year)
46%
Beta vs S&P 500
0.76

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±9.1%
After a week
4 up, 7 down
typical move ±10.6%
After a month
4 up, 7 down
typical move ±15.0%
Results releasedNext dayS&P 500 next day5 days21 days
October 28, 2026 +0.7% 0.0% — —
July 29, 2026 −3.2% +0.1% +2.4% +15.1%
April 29, 2026 −12.6% +1.0% −18.5% −18.4%
February 4, 2026 −4.4% −1.7% −3.6% −18.9%
October 22, 2025 +36.6% +0.1% +33.8% +15.4%
July 23, 2025 +13.5% +0.9% −5.4% −11.0%
April 23, 2025 −6.7% +3.7% −8.6% −12.1%
January 29, 2025 −4.2% +0.1% −3.7% −21.0%
October 23, 2024 +9.8% −0.7% +11.8% +22.5%
July 24, 2024 +9.4% −2.8% +10.0% −18.6%
April 24, 2024 +0.5% −0.4% −7.5% +6.8%
January 31, 2024 −8.1% −0.3% −10.8% −5.4%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How Core Laboratories Inc.’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Cash-secured put

Not offered: fundamentals grade C (needs B+ or better).

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

Covered call

Not offered: no liquid call at or above our price target — the model says the upside is worth more than any listed strike.

For holders: sell a call at a strike at or above our fair value, so the shares are only sold at a price the model calls full value.

Collar

Not offered: no liquid put and call pair for the same expiry.

For holders of a stock trading at or above our fair value: buy a put for a floor and sell a call to pay for it.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

Core Laboratories Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Core Laboratories Inc.
$505M $510M $515M $520M $525M $530M FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $509.8M Revenue (TTM), FY24 Q1: $511.1M Revenue (TTM), FY24 Q2: $513.8M Revenue (TTM), FY24 Q3: $522.8M Revenue (TTM), FY24 Q4: $523.8M Revenue (TTM), FY25 Q1: $517.8M Revenue (TTM), FY25 Q2: $517.4M Revenue (TTM), FY25 Q3: $517.5M Revenue (TTM), FY25 Q4: $526.5M Revenue (TTM), FY26 Q1: $524.7M Revenue (TTM), FY26 Q2: $519.2M Revenue (TTM), FY26 Q3: $516.7M $516.7M

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $509.8M
FY24 Q1 $511.1M
FY24 Q2 $513.8M
FY24 Q3 $522.8M
FY24 Q4 $523.8M
FY25 Q1 $517.8M
FY25 Q2 $517.4M
FY25 Q3 $517.5M
FY25 Q4 $526.5M
FY26 Q1 $524.7M
FY26 Q2 $519.2M
FY26 Q3 $516.7M
Revenue growth, TTM YoY Core Laboratories Inc.
-2% -1% 0% 1% 2% 3% FY24 Q1 FY24 Q3 FY25 Q1 FY25 Q3 FY26 Q1 FY26 Q3 Revenue growth, TTM YoY, FY24 Q1: 1.6% Revenue growth, TTM YoY, FY24 Q2: 0.8% Revenue growth, TTM YoY, FY24 Q3: 2.7% Revenue growth, TTM YoY, FY24 Q4: 2.8% Revenue growth, TTM YoY, FY25 Q1: 1.3% Revenue growth, TTM YoY, FY25 Q2: 0.7% Revenue growth, TTM YoY, FY25 Q3: -1.0% Revenue growth, TTM YoY, FY25 Q4: 0.5% Revenue growth, TTM YoY, FY26 Q1: 1.3% Revenue growth, TTM YoY, FY26 Q2: 0.3% Revenue growth, TTM YoY, FY26 Q3: -0.1% -0.1%

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period Revenue growth, TTM YoY
FY24 Q1 1.6%
FY24 Q2 0.8%
FY24 Q3 2.7%
FY24 Q4 2.8%
FY25 Q1 1.3%
FY25 Q2 0.7%
FY25 Q3 -1.0%
FY25 Q4 0.5%
FY26 Q1 1.3%
FY26 Q2 0.3%
FY26 Q3 -0.1%
Operating margin (TTM) Core Laboratories Inc.
7% 8% 9% 10% 11% 12% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: 10.7% Operating margin (TTM), FY24 Q1: 11.1% Operating margin (TTM), FY24 Q2: 10.5% Operating margin (TTM), FY24 Q3: 11.3% Operating margin (TTM), FY24 Q4: 11.2% Operating margin (TTM), FY25 Q1: 10.5% Operating margin (TTM), FY25 Q2: 10.4% Operating margin (TTM), FY25 Q3: 10.6% Operating margin (TTM), FY25 Q4: 10.7% Operating margin (TTM), FY26 Q1: 10.3% Operating margin (TTM), FY26 Q2: 9.2% Operating margin (TTM), FY26 Q3: 7.5% 7.5%

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 10.7%
FY24 Q1 11.1%
FY24 Q2 10.5%
FY24 Q3 11.3%
FY24 Q4 11.2%
FY25 Q1 10.5%
FY25 Q2 10.4%
FY25 Q3 10.6%
FY25 Q4 10.7%
FY26 Q1 10.3%
FY26 Q2 9.2%
FY26 Q3 7.5%
FCF margin (TTM) Core Laboratories Inc.
0% 5% 10% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: 2.8% FCF margin (TTM), FY24 Q1: 4.3% FCF margin (TTM), FY24 Q2: 5.8% FCF margin (TTM), FY24 Q3: 8.4% FCF margin (TTM), FY24 Q4: 8.5% FCF margin (TTM), FY25 Q1: 8.9% FCF margin (TTM), FY25 Q2: 8.1% FCF margin (TTM), FY25 Q3: 7.4% FCF margin (TTM), FY25 Q4: 4.9% FCF margin (TTM), FY26 Q1: 4.3% FCF margin (TTM), FY26 Q2: 2.9% FCF margin (TTM), FY26 Q3: 2.0% 2.0%

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 2.8%
FY24 Q1 4.3%
FY24 Q2 5.8%
FY24 Q3 8.4%
FY24 Q4 8.5%
FY25 Q1 8.9%
FY25 Q2 8.1%
FY25 Q3 7.4%
FY25 Q4 4.9%
FY26 Q1 4.3%
FY26 Q2 2.9%
FY26 Q3 2.0%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Core Laboratories took in during FY2025, followed through to profit: what it cost to make, what went on running the business, and what was left after tax.

  1. Revenue $527M
  2. Cost of revenue $418M · 79.3%
  3. Gross profit $109M · 20.7%
  4. Selling, general and admin $45.4M · 8.6%
  5. Other operating costs $7M · 1.3%
  6. Operating income $56.5M · 10.7%
  7. Income tax $15.5M · 2.9%
  8. Interest and other $11.3M · 2.1%
  9. Net income $29.7M · 5.6%

Shares of revenue. Source: Core Laboratories's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Sept 2026
Income
Revenue 470 490 510 524 527 517
Gross profit — 96 110 103 109 99
EBITDA 64 59 70 74 71 54
Operating income 45 42 55 59 56 39
Net income 20 19 37 31 30 16
Diluted EPS $0.42 $0.42 $0.77 $0.66 $0.63 $0.33
Growth (year on year)
Revenue — +4.1% +4.1% +2.8% +0.5% −0.1%
EBITDA — −8.0% +20.0% +4.4% −3.3% −22.4%
Operating income — −8.3% +31.6% +7.2% −3.6% −29.0%
Net income — −1.4% +88.5% −14.4% −5.5% −51.6%
Diluted EPS — 0.0% +83.3% −14.3% −4.5% −51.0%
Margins
Gross margin — 19.6% 21.5% 19.7% 20.7% 19.1%
EBITDA margin 13.6% 12.0% 13.8% 14.0% 13.5% 10.4%
Operating margin 9.6% 8.5% 10.7% 11.2% 10.7% 7.5%
Net margin 4.2% 4.0% 7.2% 6.0% 5.6% 3.0%
Free-cash-flow margin 4.9% 3.0% 2.8% 8.5% 4.9% 2.0%
Cash flow
Cash from operations 37 25 25 56 37 25
Capital spending 14 10 11 12 11 14
Free cash flow 23 15 14 45 26 10
Stock-based pay 19 8 14 4 7 8
Free cash flow after stock pay 4 7 0 41 19 2
Balance sheet
Cash 18 15 15 19 23 21
Total debt 0 175 166 128 113 115
Net debt (negative = net cash) −18 160 151 109 90 93
Diluted shares 47m 47m 48m 48m 47m 47m
Returned to shareholders
Dividends 2 2 2 2 2 2
Buybacks 8 4 2 5 12 10
Total returned 10 6 4 7 14 12

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 5 checks passed · September 30, 2026
What it owns · $594m
Short-term assets $225mLonger-term assets $368m
What it owes, and who funded it · $381m
Short-term liabilities $103mShareholders' equity $278m
  • Short-term assets cover short-term liabilities $225m of assets due within a year against $103m of liabilities due within a year.
  • Short-term assets cover long-term liabilities Not assessable from the reported split. Not assessable.
  • More cash than debt $21m of cash against $112m of debt.
  • Debt below 40% of shareholders' equity Debt is 40% of equity.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt $25m of operating cash flow against $112m of debt.
  • Operating profit covers interest at least five times over Operating income of $39m against $11m of interest.

From Core Laboratories Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q3 TTM
Buybacks (TTM)
$10.4M
Dividends (TTM)
$1.8M
Returned to shareholders
118%
of free cash flow
Buybacks, last 3 fiscal years
$19.9M
Diluted share count
−1.1%
year over year
Total shareholder yield
2.6%
dividends 0.4% + buybacks 2.2% of market value
Dividend payout ratio
12%
of net income paid out
Days sales outstanding
82 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in oil & gas equipment & services
Last 12 months unless stated CLB RNGR BOOM KLXE OIS TTI Median
Revenue, last 12 months $517m $607m $609m $636m $650m $657m $1.2bn
Revenue growth, last 12 months −0.1% 6.1% −1.6% −4.8% −0.7% 6.1% 3.7%
Revenue growth, 3-year average 0.5% −2.4% −5.4% −11.5% −5.7% 1.9% 2.0%
Revenue growth, latest quarter −1.8% 25.5% 14.1% 5.2% 2.8% 9.6% 7.3%
Gross margin 19.1% — 21.5% 21.0% 20.2% 22.5% 21.1%
Operating margin 7.5% 3.7% 0.7% −2.4% −14.0% 6.9% 7.3%
Operating margin, 3-year average 9.8% 4.4% −5.3% −2.0% −3.5% 8.5% 7.2%
Net margin 3.0% 2.4% −1.2% −9.7% −16.5% 1.4% 2.6%
Cash from operations / revenue 4.8% 10.0% 3.7% 5.8% 7.3% 9.6% 11.7%
Free-cash-flow margin 2.0% 3.9% 2.0% −0.3% 5.2% −6.4% 2.0%
Free-cash-flow margin, 3-year average 5.9% 6.7% 4.4% −1.4% 3.4% −2.0% 4.0%
Stock pay / revenue 1.6% 1.1% 0.3% 0.3% 1.6% 1.1% 1.1%
Change in share count −1.1% 1.3% 1.0% 13.8% −2.2% 5.8% 1.0%

Median of all 35 companies we cover in oil & gas equipment & services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

35 oil & gas equipment & services companies
Measure Company Peer median Rank
Revenue growth Growth -0.1% 3.7% 22 of 35
Change in growth rate Growth -0.5pp +1.5pp 24 of 34
Gross margin Profitability 19.1% 21.5% 16 of 21
Operating margin Profitability 7.5% 7.2% 14 of 32
Net margin Profitability 3.0% 2.6% 17 of 35
Free-cash-flow margin Cash generation 2.0% 2.0% 17 of 35
Stock pay as % of revenue Cash generation 1.6% 1.1% 24 of 32
Long-term debt as % of assets Balance sheet 18.9% 22.6% 14 of 32
Change in share count Balance sheet -1.1% 1.0% 9 of 31
Days sales outstanding Balance sheet 82 days 74 days 19 of 26

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Operating Segment Reservoir Description $348M 66.0% ▲ 0.4%
Operating Segment Production Enhancement $179M 34.0% ▲ 0.6%
Corporate and Other $0 0.0% —
Products and services
Line of business Revenue Share YoY
Services $399M 75.9% ▲ 2.9%
Products $127M 24.1% ▼ 6.3%
Geography
Region Revenue Share YoY
Outside the US $351M 66.7% ▲ 1.8%
United States $175M 33.3% ▼ 2.0%

From Core Laboratories Inc.'s 10-K filed March 23, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$613M
Institutions reporting
184
Shares held vs prior quarter
▲ 4.3%
Positions opened / closed
28 / 31

Top buyers and sellers, Q2 2026: 84 institutions bought and 100 sold ; the biggest buyer was Schroder Investment Management Group (+1.5M shares) and the biggest seller Disciplined Growth Investors Inc (−1.9M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Ariel Investments, LLC $164M 14.1M 26.8% ▲ 6.9%
Blackrock, Inc. $86.9M 7.5M 14.2% ▲ 3.5%
Disciplined Growth Investors Inc $35.4M 3.0M 5.8% ▼ 38.4%
Earnest Partners LLC $34.3M 2.9M 5.6% ▼ 3.8%
State Street Corp $25.4M 2.2M 4.1% ▲ 5.6%
Cwa Asset Management Group, LLC $20.4M 1.8M 3.3% ▲ 0.8%
Vanguard Capital Management LLC $18.5M 1.6M 3.0% ▼ 1.8%
Dimensional Fund Advisors LP $18M 1.5M 2.9% ▲ 14.5%
Schroder Investment Management Group $16.9M 1.5M 2.8% New
Vanguard Portfolio Management LLC $14.9M 1.3M 2.4% ▲ 1.6%
Geode Capital Management, LLC $13.9M 1.2M 2.3% ▲ 4.9%
Gendell Jeffrey L $12.7M 1.1M 2.1% ▲ 68.2%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Core Laboratories Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $53,900 1 trade by 1 insider, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $53,900 net buying
Insider Date Trade Shares Price Value
Bruno Lawrence Chairman and CEO July 31, 2026 Buy 5,000 $10.78 $53,900

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 17 trades and filings

No trades in Core Laboratories Inc. disclosed in the last 12 months; 17 earlier trades on record.

  • John W. Rose(R-TN 6):Sale (full), $1,001 - $15,000, traded November 12, 2019, filed December 11, 2019
  • Thomas J. Rooney(FL):Sale (full), $15,001 - $50,000, traded December 10, 2018, filed January 14, 2019
  • Thomas MacArthur(NJ):Sale (partial), $1,001 - $15,000, traded October 24, 2018, filed December 6, 2018

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around February 3, 2027 estimated from the company's past filing pattern, not announced

  • October 28, 2026
  • July 29, 2026
  • April 29, 2026
  • February 4, 2026
  • October 22, 2025
  • July 23, 2025

Recent SEC filings

Data status

When each part of this page on Core Laboratories Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Core Laboratories Inc. in brief

What does Core Laboratories Inc. do?
Core Laboratories Inc. is a US-listed company in the oil & gas equipment & services industry. Its financial year ends in December.
What is Core Laboratories Inc.'s stock ticker?
Core Laboratories Inc. trades under the ticker CLB on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Core Laboratories Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Core Laboratories Inc. reported revenue of $517M, 0.1% lower than a year earlier, according to its SEC filings.
What is Core Laboratories Inc.'s free cash flow?
Core Laboratories Inc.'s free-cash-flow margin is 2.0% of revenue over the trailing twelve months, ranking 17 of the 35 oil & gas equipment & services companies we cover.
What is Core Laboratories Inc.'s fair value (intrinsic value) per share?
Our discounted-cash-flow model of Core Laboratories Inc.'s free cash flow after stock-based pay gives ~$9.6 per share in the base case, and ~$6.6–$13 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Core Laboratories Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Ariel Investments, LLC, Blackrock, Inc. and Disciplined Growth Investors Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Core Laboratories Inc. buying back stock, and does it pay a dividend?
Core Laboratories Inc. spent $10.4M on share repurchases over the trailing twelve months, and its diluted share count fell 1.1% over the year.
What is Core Laboratories Inc.'s market cap?
On November 2, 2026, Core Laboratories Inc.'s market capitalisation was about $475M, with a price-to-earnings ratio of 30.5 and net debt of $93.4M. Market figures come from third-party market data and may be delayed.
Does Core Laboratories Inc. pay a dividend?
Yes: Core Laboratories Inc. paid $1.8M in dividends over the trailing twelve months, a dividend yield of 0.40% and a payout ratio of 11.9%.
How much debt does Core Laboratories Inc. have?
Core Laboratories Inc.'s debt-to-equity ratio is 40.5%, from its latest balance sheet. The financial health section below sets out its other solvency checks.
Who are Core Laboratories Inc.'s competitors?
In our Oil & Gas Equipment & Services peer group, the companies closest to Core Laboratories Inc. are Ranger Energy Services, Inc., DMC Global Inc., KLX Energy Services Holdings, Inc., OIL States International, Inc and Tetra Technologies Inc. The side-by-side comparison below sets their revenue, margins and growth against Core Laboratories Inc.'s.
Are insiders buying or selling Core Laboratories Inc. stock?
Over the last 12 months, Core Laboratories Inc.'s directors and officers reported 1 open-market purchases and 0 sales on Form 4. The insider trading page charts every trade.
When is Core Laboratories Inc.'s next earnings date?
Around February 3, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Core Laboratories Inc. announces its own schedule.